Search
Close this search box.

Accuray at ESTRO 2023 | Booth 250

Certainty Matters.

As healthcare providers face unprecedented changes, certainty matters more than ever. At ESTRO 2023, see how our advanced technology can help give clinicians the tools to achieve best-in-class clinical workflows for a full spectrum of clinical indications. How clinical evidence gives patients greater certainty that they’re getting the best possible treatment. And how that combination of powerful technology and clinical evidence give healthcare organizations greater certainty to make confident investments to drive future success.

The Radixact® System, a Comprehensive
Breast Cancer System

Visit Accuray ESTRO booth #250 to see how the innovative VitalHold* Breast Package gives clinicians the certainty to treat virtually all breast cancer cases with the Radixact System — maximizing patient comfort and optimizing patient outcomes.

Easy Set-Up

Perform positioning with the clinical flexibility of SGRT and ClearRT™ helical kVCT imaging for efficient and effective patient set-up.

Confident Monitoring

Gate the beam automatically with SGRT for DIBH treatments using TomoDirect™ delivery.

Fast Delivery

Treat precisely in as little as 2 minutes with added patient comfort.

Accuray Symposium

Advances in Hypofractionation for Breast and Prostate Cancer

The Accuray Symposium features leading clinical experts discussing the most recent and promising clinical research on hypofractionated radiotherapy treatments for breast and prostate cancers.

Opening & Closing Insights on Hypofractionation

Dr. Seth Blacksburg, SVP, Chief Medical Officer, Accuray

Prof. Barbara Alicja Jereczek-Fossa, Full Professor of Radiation Oncology, University of Milan and Chair of Division of Radiation Oncology of European Institute of Oncology, Milan, Italy

From the Crystal Study with Extreme Hypofractionation to Moderate Hypofractionation

Dr. Maria Cristina Leonardi, Deputy Director, Division of Radiotherapy, IEO European Institute of Oncology, Milan, Italy

What We Have Learnt from PACE Multicenter, International Phase 3 Randomized Controlled Study

Prof. Nicholas van As, Medical Director and Consultant Clinical Oncologist of The Royal Marsden NHS Foundation Trust and Professor in Precision Prostate Radiotherapy at The Institute of Cancer Research, London and Lead Investigator of the PACE Trial

20+ Years of Evidence

Accuray technologies build on more than two decades of clinical evidence and real-world use. Access publications and webinars from around the globe, including evidence for a wide range of treatment sites.

Talk to an Expert

Talk to an Expert

Services

Industry-leading service to support your ongoing success, from speedy install and optimization, to proactive monitoring and unrivalled on-site service, to smart upgrade paths to keep your system at the leading edge.

Treatment Solutions

From robotic to helical radiation therapy delivery, we invent unique, market-changing solutions that are designed to deliver radiation treatments across a full spectrum of patient needs.

Treatment Centers

What's New

Your go-to source for staying informed about our advancements.

Why Accuray

Accuray is expanding radiation therapy: our products can deliver it accurately, precisely and effectively, from oncology to neuro-radiosurgery and beyond.